New drug combo targets Hard-to-Treat cancers
NCT ID NCT04250155
First seen Jan 05, 2026 · Last updated May 01, 2026 · Updated 17 times
Summary
This study tests a new experimental drug called XmAb24306, given alone or with another drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check safety and find the best dose. About 195 adults with various solid tumors will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center - PPDS
Seoul, 05505, South Korea
-
City of Hope Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
-
Clinica Universidad de Navarra-Madrid
Madrid, 28027, Spain
-
Clinica Universitaria de Navarra
Pamplona, Navarre, 31008, Spain
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Lombardy, 20133, Italy
-
GasthuisZusters Antwerpen
Wilrijk, Antwerp, 2610, Belgium
-
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam, North Holland, 1066 CX, Netherlands
-
Honor Health Research Institute
Scottsdale, Arizona, 85258, United States
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital de Clinicas de Porto Alegre HCPA PPDS
Porto Alegre, Rio Grande do Sul, 90560-030, Brazil
-
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, 01246-000, Brazil
-
Istituto Clinico Humanitas
Rozzano, Lombardy, 20089, Italy
-
Istituto Europeo Di Oncologia
Milan, Lombardy, 20141, Italy
-
Parkville Cancer Clinical Trial Unit (PCCTU)
Melbourne, Victoria, 3000, Australia
-
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START Madrid-FJD, Hospital Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Samsung Medical Center - PPDS
Seoul, 06351, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, 13620, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital Yonsei University Health System - PPDS
Seoul, 03722, South Korea
-
Stanford Health Centre - Palo Alto
Palo Alto, California, 94304, United States
-
Universitair Medisch Centrum Groningen
Groningen, 9713 GZ, Netherlands
-
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158-2545, United States
-
Yale University
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.